The Trump administration's decision late Tuesday to wind down funding for new mRNA vaccines drew swift criticism from medical researchers and public health authorities. Driving the news: Kennedy said the government would pull $500 million in mRNA development funding from its emergency preparedness agency in order to focus on "safer, broader vaccine platforms." - No new mRNA based projects will be initiated, HHS said. Some final-stage contracts for targets like pandemic bird flu will run their course.
What they're saying: "I've tried to be objective & non-alarmist in response to current HHS actions — but quite frankly this move is going to cost lives," Jerome Adams, who served as surgeon general during President Trump's first administration, wrote on X. Zoom out: Researchers at Penn Medicine are developing mRNA vaccines for infections including avian bird flu, coronaviruses, C. difficile, genital herpes, hepatitis C, HIV, influenza, leptospirosis, malaria, norovirus and tuberculosis. - Moderna has mRNA vaccines in various levels of development to defend against RSV, HIV, Lyme disease, Mpox, several cancers and cystic fibrosis.
What we're watching: As of January, more than 120 clinical trials were testing the potential for mRNA vaccines in cancer treatment across various malignancies, according to research published in the National Library of Medicine. - Researchers believe mRNA systems can be used to train the body's immune system to attack malignancies, creating a personalized medicine approach that could make certain cancers more treatable.
|